Trial · NCT07004972
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of serious Treatment Emergent Adverse Events (TEAEs) | Up to Week 48 | |
| Secondary | Number of participants with major adverse cardiac events | Up to Week 48 | Major adverse cardiac events includes cardiovascular \[CV\] death, non-fatal stroke, nonfatal myocardial infarction and hospitalization for heart failure |
| Secondary | Number of participants with CV hospitalization | Up to Week 48 | |
| Secondary | Number of participants with heart failure (HF) events | Up to Week 48 | HF includes HF related hospitalizations and urgent emergency room \[ER\]/outpatient visits |
| Secondary | Number of participants with atrial fibrillation/flutter | Up to Weeks 48 | |
| Secondary | Number of participants with syncope | Up to Week 48 | |
| Secondary | Number of participants with left ventricular ejection fraction (LVEF) < 50% | Up to Week 30 | |
| Secondary | Number of participants with left ventricular ejection fraction (LVEF) < 45% | Up to Week 30 | |
| Secondary | Number of participants with left ventricular ejection fraction (LVEF) < 40% | Up to Week 30 | |
| Secondary | Number of participants with left ventricular ejection fraction (LVEF) < 30% | Up to Week 30 | |
| Secondary | Number of participants with non-serious AEs | Up to Week 48 | |
| Secondary | Change from baseline to Week 30 in Valsalva left ventricular outflow tract (LVOT) peak gradient | Up to Week 30 | |
| Secondary | Change from baseline to Week 30 in resting LVOT peak gradient | Up to Week 30 | |
| Secondary | Change from baseline to Week 30 in hs-troponin-I | Up to Week 30 | |
| Secondary | Change from baseline to Week 30 in N-terminal pro b-type natriuretic peptide (NT-proBNP) | Up to Week 30 | |
| Secondary | Proportion of participants with at least 1 class improvement in New York Heart Association (NYHA) functional class from baseline to Week 30 | Up to Week 30 | The New York Heart Association (NYHA) functional classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Heart failure classification will be assessed by the Investigator at specified timepoints in the study. NYHA class at Week 30 will be compared to baseline and the proportion of participants with an improvement of at least one class will be determined. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07004972/registered